The Eyerising Myopia Management Device is an innovative, home-use device that utilises repeated low-level red-light (RLRL) therapy to slow the progression of myopia in children aged three to 16 years.
Using visible 650 nm red light emitted via laser diodes, the treatment requires children to look into the device for three minutes, twice daily, five days a week. The therapy is non-invasive, user-friendly, and has demonstrated strong effect in slowing myopia,1 including in an Australian population.2 Real-time compliance monitoring is available via the Eyerising portal, enabling parents and practitioners to track adherence and optimise outcomes as part of their myopia management.
Contact: Eyerising International (AUS) info@eyerisinginternational.com or (NZ) enquiries@oic.co.nz
References
- Jiang Y, et al. Ophthalmology. 2022. doi: 10.1016/j.ophtha.2021.11.023.
- Deen N, et al. Ophthalmic Epidemiol. 2025. doi: 10.1080/09286586.2025.2500020. Epub ahead of print.
